Clinical Trials Logo

Clinical Trial Summary

This study employs a 2-stage design that aims to evaluate the efficacy and safety of ENV- 101, a potent Hedgehog (Hh) pathway inhibitor, in patients with refractory advanced solid tumors characterized by loss of function (LOF) mutations in the Patched-1 (PTCH1) gene. Stage 1 of this study will enroll approximately 44 patients randomized between two dose levels. As appropriate, Stage 2 of the study will expand enrollment based on the results of Stage 1.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05199584
Study type Interventional
Source Endeavor Biomedicines, Inc.
Contact Endeavor Clinical Trials
Phone 1-858-727-3199
Email [email protected]
Status Recruiting
Phase Phase 2
Start date May 2022
Completion date May 2024